| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | DR4; DRB4; HLA class II histocompatibility antigen; HLA-DRB4;;HLA DRB4 |
| WB Predicted band size | 30 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human HLA DRB4 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于HLA-DRB4抗体的模拟参考文献示例(注：以下内容为虚构示例，仅供格式参考)：
---
1. **文献名称**: *HLA-DRB4 Antibodies in Rheumatoid Arthritis: Clinical Correlations*
**作者**: Smith A, et al.
**摘要**: 该研究检测了类风湿性关节炎患者血清中的HLA-DRB4自身抗体，发现其阳性率与关节破坏程度及炎症标志物(如CRP)呈正相关，提示抗体可能参与疾病进展。
2. **文献名称**: *Impact of HLA-DRB4 Mismatch on Kidney Transplant Outcomes*
**作者**: Jones B, et al.
**摘要**: 通过回顾性队列分析，研究发现受体中预存的HLA-DRB4供体特异性抗体与移植物排斥反应风险增加相关，强调了移植前抗体筛查的重要性。
3. **文献名称**: *HLA-DRB4 Autoantibodies in Systemic Lupus Erythematosus*
**作者**: Lee C, et al.
**摘要**: 该文首次报道系统性红斑狼疮患者中HLA-DRB4自身抗体的存在，并发现其与神经精神性狼疮和肾脏受累显著相关，提示潜在病理机制。
4. **文献名称**: *HLA-DRB4 Antibody Detection via Luminex Assay: Technical Validation*
**作者**: Garcia D, et al.
**摘要**: 研究评估了Luminex单抗原检测法对HLA-DRB4抗体的敏感性和特异性，为临床实验室标准化提供了数据支持。
---
如需真实文献，建议通过PubMed或Google Scholar检索关键词“HLA-DRB4 antibody”、“HLA-DRB4 autoimmunity”等，并筛选近年的临床或基础研究论文。
HLA-DRB4 is a human leukocyte antigen (HLA) class II molecule encoded by the DRB4 gene, part of the HLA-DRβ locus within the major histocompatibility complex (MHC) on chromosome 6. It is primarily expressed on antigen-presenting cells and plays a critical role in immune regulation by presenting peptide antigens to CD4+ T cells, thereby initiating adaptive immune responses. HLA-DRB4 is polymorphic, with multiple alleles identified, though its expression is not universal; it is only present in specific HLA-DR haplotypes (e.g., DR4. DR7. DR9).
Antibodies targeting HLA-DRB4 are clinically significant in transplantation and autoimmune diseases. In organ or hematopoietic stem cell transplantation, preformed or de novo HLA-DRB4 antibodies can trigger immune-mediated rejection by binding to donor cells, leading to graft dysfunction or failure. These antibodies are also implicated in autoimmune conditions, such as rheumatoid arthritis, where molecular mimicry or epitope spreading may drive their production. Detection methods like solid-phase assays (e.g., Luminex) are used to identify HLA-DRB4 antibodies in sensitized patients, aiding in donor selection and desensitization protocols.
However, interpreting HLA-DRB4 antibody results is complicated by cross-reactivity with other HLA-II antigens and varying clinical relevance based on antibody strength/specificity. Research continues to clarify its role in disease mechanisms and improve risk stratification in transplantation.
×
